טוען...
The Three P’s: Parotid, PD-L1, and Pembrolizumab
We present a case of recurrent, platinum-refractory undifferentiated carcinoma of the parotid which was treated with checkpoint inhibitor, Pembrolizumab, and achieved a complete response to therapy. We review the literature of checkpoint inhibitor use in undifferentiated carcinoma of the parotid.
שמור ב:
| Main Authors: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Hindawi Limited
2019-01-01
|
| סדרה: | Case Reports in Oncological Medicine |
| גישה מקוונת: | http://dx.doi.org/10.1155/2019/2305315 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|